{"entity":{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","aka":[],"tldr":"Pancreatic cancer surgeon-scientist who directs UC San Diego Moores Cancer Center, an NCI-designated comprehensive cancer center.","summary":"Diane M. Simeone, MD, is Director of UC San Diego Moores Cancer Center and Professor of Surgery and Pharmacology. She is a surgical oncologist and pancreatic cancer researcher whose work spans pancreatic cancer stem cells, early detection in high-risk individuals and the Precision Promise adaptive platform trial. She previously directed the Pancreatic Cancer Center at NYU Langone.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simeone+DM%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","pancreatic cancer","surgical oncology"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"role":"Director, Moores Cancer Center; Koman Family Presidential Director's Chair","institutionId":"ucsd-moores","specialisms":["Pancreatic cancer","Surgical oncology","Cancer early detection"],"profiles":[{"label":"Institution profile","url":"https://moorescancercenter.ucsd.edu/about/leadership/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Simeone+DM%5BAuthor%5D"}],"papers":[{"title":"Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma","journal":"Gastroenterology","year":2026,"doi":"10.1053/j.gastro.2025.08.034"},{"title":"A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals","journal":"Cancers","year":2025,"doi":"10.3390/cancers17111866"},{"title":"Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium","journal":"International Journal of Cancer","year":2026,"doi":"10.1002/ijc.70592"}],"orcid":"0000-0001-5142-3087"},"route":"/people/diane-simeone/","neighbours":{"cancer":[{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"institution":[{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/"}],"journal":[{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/"}],"paper":[{"id":"paper-caps-consortium-surveillance-recommendations-gut-2020","kind":"paper","name":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","route":"/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/"},{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/"},{"id":"paper-gonda-precede-consortium-recommendations-gastroenterology-2021","kind":"paper","name":"Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium","route":"/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]}}